ReviewClinical medicine (London, England)2016
New concepts in the pathogenesis and presentation of Parkinson's disease.
Review in Clinical medicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 57 citations in OpenAlex.
- MRI Epicenters Differentiate Spatiotemporal Patterns of Neurodegeneration in Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Test, track, treat using wearable sensors for management of Parkinson's disease: 12‑month prospective observational United Arab Emirates study using Parkinson's Kinetograph (EmPark-PKG Study).Journal of neural transmission (Vienna, Austria : 1996) · 2025Observational
- Risk factors and predictors for Lewy body dementia: a systematic review.NPJ dementia · 2025Article
- Experiences of People Living with Parkinson's Disease in Care Homes: A Qualitative Systematic Review.Nursing reports (Pavia, Italy) · 2024Review
- Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson's disease.Nature communications · 2023Article
- The Dashboard Vitals of Parkinson's: Not to Be Missed Yet an Unmet Need.Journal of personalized medicine · 2022Article
- First Two-Year Observational Exploratory Real Life Clinical Phenotyping, and Societal Impact Study of Parkinson's Disease in Emiratis and Expatriate Population of United Arab Emirates 2019-2021: The EmPark Study.Journal of personalized medicine · 2022Article
- Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease.International journal of molecular sciences · 2022Review
- Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.Diagnostics (Basel, Switzerland) · 2022Review
- Efficacy of Traditional Herbal Medicine Treatment Based on Pattern Identification for Idiopathic Parkinson's Disease: A Protocol for Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Association between Temporomandibular Joint Disorder and Parkinson's Disease.Brain sciences · 2021Article
- Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies.Redox biology · 2021Review
- Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing.NPJ Parkinson's disease · 2021Review
- Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field.Journal of neurology · 2021Review
- The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration.Frontiers in aging neuroscience · 2021Review
- Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?PloS one · 2021Article
- Subthalamic deep brain stimulation improves sleep and excessive sweating in Parkinson's disease.NPJ Parkinson's disease · 2020Article
- Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1.Orphanet journal of rare diseases · 2019Article
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.Nature reviews. Drug discovery · 2018Review
- The Luxembourg Parkinson's Study: A Comprehensive Approach for Stratification and Early Diagnosis.Frontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) was first described by James Parkinson in 1817. He noted the complex nature of this condition and that non-motor symptoms (NMS) underpinned the classic motor symptoms of PD. The concept of what PD is has therefore undergone substantial changes and it is now recognised that PD is a combined motor and non-motor syndrome and NMS are present during the prodromal phase of PD, starting up to 20 years before the first clinical motor signs emerge. PD may originate from pathology in the gut, olfactory bulb and lower brainstem rather than in the substantia nigra. Complex phenotypes of PD may exist where clinical NMS overshadow motor features. Therapy needs to be adjusted based on motor and non-motor loads, ideally using validated tools. Recently, a multimodal biomarker battery in PD has emerged and might play an important role in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.